This is a preview of subscription content, log in via an institution to check access.
References
Cockburn, I. & Henderson, R. Public-Private Interaction and the Productivity of Pharmaceutical Research. National Bureau of Economic Research (NBER) Working Paper 6018 (NBER, Cambridge, MA, 1997).
Powell, W.W., Korput, K.W. & Smith-Doerr, L. Administr. Sci. Quart. 41, 116–145 (1996).
Murray, F. Res. Policy 31, 1389–1403 (2002).
Henderson, R., Orsenigo, L. & Pisano, G.P. in Sources of Industrial Leadership, Studies of Seven Industries (eds. Mowery, D. & Nelson, R.) 267–311 (Cambridge University Press, Cambridge, UK, 1999).
McKelvey, M. Evolutionary Innovations, the Business of Biotechnology (Oxford University Press, Oxford, 1996).
Zucker, L.G. & Darby, M.R. Proc. Natl. Acad. Sci. USA 93, 12709–12716 (1996).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kneller, R. The origins of new drugs. Nat Biotechnol 23, 529–530 (2005). https://doi.org/10.1038/nbt0505-529
Issue Date:
DOI: https://doi.org/10.1038/nbt0505-529
- Springer Nature America, Inc.
This article is cited by
-
The importance of new companies for drug discovery: origins of a decade of new drugs
Nature Reviews Drug Discovery (2010)
-
Can literature analysis identify innovation drivers in drug discovery?
Nature Reviews Drug Discovery (2009)
-
Leveraging biotech's drug discovery expertise for neglected diseases
Nature Biotechnology (2009)
-
Erratum: Corrigendum: The origins of new drugs
Nature Biotechnology (2005)
-
Finding improved medicines: the role of academic–industrial collaboration
Nature Reviews Drug Discovery (2005)